drugset / Trial / NCT00682370
Effects of Heme Arginate in Healthy Male Subjects
RandomizedCrossoverSingle-blindTreatment
Summary
Heme oxygenase 1 (HO-1) serves as a protective gene. It has been shown that one factor modulating HO-1 activity is a genetic variation in the HO-1 gene (functional GT length polymorphism in the promotor region). Heme arginate is a strong inducer of HO-1 as shown in several animal experimental studies. The aim of this clinical trial is to evaluate the HO-1 stimulation of heme arginate in healthy humans.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | heme arginate | Small molecule | 0.3 mg/kg | Intravenous |
| Subject | heme arginate | Small molecule | 1 mg/kg | Intravenous |
| Subject | heme arginate | Small molecule | 3 mg/kg | Intravenous |
Indications
No indication recorded.